版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
ICS11.120.99
CCSC01
43
湖南省地方標(biāo)準(zhǔn)
DB43/T2135—2021
藥物臨床試驗(yàn)受試者招募管理技術(shù)
服務(wù)規(guī)范
Drugclinicaltrialsubjectsrecruitmentmanagement
technicalservicespecification
2021-08-03發(fā)布2021-10-03實(shí)施
湖南省市場(chǎng)監(jiān)督管理局發(fā)布
DB43/T2135—2021
目次
前言························································································································Ⅲ
1范圍·····················································································································1
2規(guī)范性引用文件······································································································1
3術(shù)語(yǔ)和定義············································································································1
4縮略語(yǔ)··················································································································2
5基本原則···············································································································2
5.1知情同意原則···································································································2
5.2控制風(fēng)險(xiǎn)原則···································································································3
5.3免費(fèi)和補(bǔ)償原則································································································3
5.4保護(hù)隱私原則···································································································3
5.5依法賠償原則···································································································3
5.6特殊保護(hù)原則···································································································3
6招募組織/機(jī)構(gòu)········································································································3
7受試者招募············································································································4
7.1招募方式·········································································································4
7.2招募流程·········································································································4
8受試者管理············································································································5
8.1依從性管理······································································································5
8.2出組后跟蹤管理································································································5
8.3人文關(guān)懷管理···································································································5
9受試者權(quán)益和安全···································································································5
9.1受試者權(quán)益······································································································5
9.2受試者隱私保護(hù)································································································6
10質(zhì)量控制··············································································································6
10.1數(shù)據(jù)管理·······································································································6
10.2評(píng)價(jià)改進(jìn)·······································································································6
參考文獻(xiàn)····················································································································7
I
DB43/T2135—2021
前言
本文件按照GB/T1.1—2020《標(biāo)準(zhǔn)化工作導(dǎo)則第1部分:標(biāo)準(zhǔn)化文件的結(jié)構(gòu)和起草規(guī)則》的規(guī)
定起草。
請(qǐng)注意本文件的某些內(nèi)容可能涉及專利。本文件的發(fā)布機(jī)構(gòu)不承擔(dān)識(shí)別專利的責(zé)任。
本文件由湖南省藥品監(jiān)督管理局提出并歸口。
本文件起草單位:長(zhǎng)沙先領(lǐng)醫(yī)藥科技有限公司、中南大學(xué)湘雅醫(yī)院、中南大學(xué)湘雅二醫(yī)院、中南大
學(xué)湘雅三醫(yī)院、湖南省人民醫(yī)院、湖南省婦幼保健院、湖南省腫瘤醫(yī)院、湖南省職業(yè)病防治院、湖南省
腦科醫(yī)院、湖南省胸科醫(yī)院、長(zhǎng)沙都正生物科技股份有限公司、長(zhǎng)沙市中心醫(yī)院、長(zhǎng)沙市第一醫(yī)院、長(zhǎng)
沙市第三醫(yī)院、長(zhǎng)沙珂信腫瘤醫(yī)院、懷化市第一人民醫(yī)院、懷化市第二人民醫(yī)院、郴州市第一人民醫(yī)院、
益陽(yáng)市中心醫(yī)院、株洲市中心醫(yī)院、婁底市中心醫(yī)院、長(zhǎng)沙舍同智能科技有責(zé)任公司、長(zhǎng)沙市藥物評(píng)價(jià)
產(chǎn)業(yè)技術(shù)創(chuàng)新戰(zhàn)略聯(lián)盟。
本文件主要起草人:歐陽(yáng)冬生、李曉暉、嚴(yán)謹(jǐn)、陳桂根、謝秀芬、胡斌、陳露露、袁葉、周淦、
李昕、李卓、李偉、鄭姣、阮興強(qiáng)、徐夢(mèng)穎、鄒志、陳維明。
III
DB43/T2135—2021
藥物臨床試驗(yàn)受試者招募管理技術(shù)服務(wù)規(guī)范
1范圍
本文件規(guī)定了藥物臨床試驗(yàn)受試者招募管理技術(shù)服務(wù)的基本原則、招募組織/機(jī)構(gòu)、受試者招募、
受試者管理、受試者權(quán)益和安全和質(zhì)量控制等。
本文件適用于藥物臨床試驗(yàn)機(jī)構(gòu)及研究者、倫理委員會(huì)、合同研究組織等參與藥物臨床試驗(yàn)受試者
招募管理的組織和個(gè)人。
2規(guī)范性引用文件
本文件沒有規(guī)范性引用文件。
3術(shù)語(yǔ)和定義
下列術(shù)語(yǔ)和定義適用于本文件。
3.1
藥物臨床試驗(yàn)機(jī)構(gòu)drugclinicaltrialinstitution
具備相應(yīng)條件,按照《藥物臨床試驗(yàn)質(zhì)量管理規(guī)范》(GCP)和藥物臨床試驗(yàn)相關(guān)技術(shù)指導(dǎo)原則等要
求,開展藥物臨床試驗(yàn)的機(jī)構(gòu)。
3.2
臨床試驗(yàn)clinicaltrial
以人體(患者或健康受試者)為對(duì)象的試驗(yàn),意在發(fā)現(xiàn)或驗(yàn)證某種試驗(yàn)藥物的臨床醫(yī)學(xué)、藥理學(xué)以
及其他藥效學(xué)作用、不良反應(yīng),或者試驗(yàn)藥物的吸收、分布、代謝和排泄,以確定藥物的療效與安全性
的系統(tǒng)性試驗(yàn)。
3.3
研究者investigator
指實(shí)施臨床試驗(yàn)并對(duì)臨床試驗(yàn)質(zhì)量及受試者權(quán)益和安全負(fù)責(zé)的試驗(yàn)現(xiàn)場(chǎng)負(fù)責(zé)人。
3.4
倫理委員會(huì)ethicscommittee
由醫(yī)學(xué)、藥學(xué)及其他背景人員組成的委員會(huì),其職責(zé)是通過(guò)獨(dú)立地審查、同意、跟蹤審查試驗(yàn)方案
及相關(guān)文件、獲得和記錄受試者知情同意所用的方法和材料等,確保受試者的權(quán)益、安全受到保護(hù)。
3.5
申報(bào)者sponsor
指負(fù)責(zé)臨床試驗(yàn)的發(fā)起、管理和提供臨床試驗(yàn)經(jīng)費(fèi)的個(gè)人、組織或者機(jī)構(gòu)。
3.6
合同研究組織contractresearchorganization,CRO
指由申辦者簽訂合同授權(quán),執(zhí)行申辦者在臨床試驗(yàn)中的某些職責(zé)和任務(wù)的單位。
1
DB43/T2135—2021
3.7
臨床試驗(yàn)現(xiàn)場(chǎng)管理組織sitemanagementorganization,SMO
指協(xié)助臨床試驗(yàn)機(jī)構(gòu)進(jìn)行臨床試驗(yàn)具體操作的現(xiàn)場(chǎng)管理組織。
3.8
受試者researchparticipant
指參加一項(xiàng)臨床試驗(yàn),并作為試驗(yàn)用藥物的接受者,包括患者、健康受試者。
3.9
臨床協(xié)調(diào)員clinicalresearchcoordinator,CRC
指經(jīng)主要研究者授權(quán)在臨床試驗(yàn)中協(xié)助研究者進(jìn)行非醫(yī)學(xué)判斷的相關(guān)事務(wù)性工作,是臨床試驗(yàn)的參
與者、協(xié)調(diào)者。
3.10
知情同意informedconsent
指受試者被告知可影響其做出參加臨床試驗(yàn)決定的各方面情況后,確認(rèn)同意自愿參加臨床試驗(yàn)的過(guò)
程。該過(guò)程應(yīng)以書面的、簽署姓名和日期的知情同意書作為文件證明。
3.11
招募組織/機(jī)構(gòu)recruitorganizations/agencies
指符合GCP要求的參與受試者招募的組織機(jī)構(gòu)及個(gè)人,應(yīng)是專業(yè)的第三方招募組織或藥物臨床試驗(yàn)
機(jī)構(gòu)研究者團(tuán)隊(duì)及其成員。
3.12
生物等效性試驗(yàn)bioequivalence,BE
是指用生物利用度研究的方法,以藥代動(dòng)力學(xué)參數(shù)為指標(biāo),比較同一種藥物的相同或者不同劑型的
制劑,在相同的試驗(yàn)條件下,其活性成份吸收程度和速度有無(wú)統(tǒng)計(jì)學(xué)差異的人體試驗(yàn)。
3.13
I期臨床試驗(yàn)phaseIclinicaltrial
初步的臨床藥理學(xué)及人體安全性評(píng)價(jià)試驗(yàn)。一般在健康受試者或某類患者中進(jìn)行;具有顯著潛在毒
性的藥物通常選擇患者作為研究對(duì)象。
4縮略語(yǔ)
下列縮略語(yǔ)適用于本文件。
GCP:藥物臨床試驗(yàn)質(zhì)量管理規(guī)范(GoodClinicalPractice)
BE:生物等效性試驗(yàn)(Bioequivalence)
5基本原則
5.1知情同意原則
知情同意原則包括:
——充分告知:充分告知受試者有關(guān)臨床試驗(yàn)的所有相關(guān)事宜,包括但不限定于:臨床試驗(yàn)方案、
受試者權(quán)益、試驗(yàn)風(fēng)險(xiǎn)及受益、受試者安全性信息保護(hù)以及倫理委員會(huì)的同意意見等;
——完全理解:知情同意書等提供給受試者的口頭和書面資料均應(yīng)采用通俗易懂的語(yǔ)言和表達(dá)方
式,使受試者或者其監(jiān)護(hù)人、見證人易于理解,并給予其充分的時(shí)間和機(jī)會(huì)了解臨床試驗(yàn)的詳
2
DB43/T2135—2021
細(xì)情況,并詳盡回答其提出的與臨床試驗(yàn)相關(guān)的問(wèn)題;
——完全自愿:不應(yīng)采用強(qiáng)迫、利誘等不正當(dāng)?shù)姆绞接绊懯茉囌邊⒓踊蛘呃^續(xù)臨床試驗(yàn),受試者參
加試驗(yàn)是自愿的,可以拒絕參加或者有權(quán)在試驗(yàn)任何階段隨時(shí)退出試驗(yàn)而不會(huì)遭到歧視或者報(bào)
復(fù),其醫(yī)療待遇與權(quán)益不會(huì)受到影響。
5.2控制風(fēng)險(xiǎn)原則
優(yōu)先考慮受試者的安全和健康權(quán)益,其次考慮科學(xué)和社會(huì)獲益;權(quán)衡預(yù)期風(fēng)險(xiǎn),需滿足預(yù)期獲益大
于風(fēng)險(xiǎn),力求受試者避免傷害或傷害最小化。
5.3免費(fèi)和補(bǔ)償原則
應(yīng)公平、公正、合理地選擇受試者,對(duì)參加研究的受試者不得額外收取任何費(fèi)用,與試驗(yàn)相關(guān)的檢
查費(fèi)、住院費(fèi)、試驗(yàn)藥物均應(yīng)免費(fèi),受試者在受試過(guò)程中支出的其余合理費(fèi)用還應(yīng)給予適當(dāng)補(bǔ)償。
5.4保護(hù)隱私原則
招募機(jī)構(gòu)應(yīng)保護(hù)受試者個(gè)人信息和數(shù)據(jù),未經(jīng)授權(quán)不應(yīng)對(duì)受試者個(gè)人信息進(jìn)行查閱、復(fù)印、公開、
散播、修改、損毀等。
5.5依法賠償原則
受試者參加研究受到試驗(yàn)相關(guān)損害時(shí),應(yīng)得到及時(shí)、免費(fèi)治療,并依據(jù)法律法規(guī)及雙方約定得到賠
償,申報(bào)者可通過(guò)購(gòu)買相關(guān)保險(xiǎn)提高賠付能力。
5.6特殊保護(hù)原則
對(duì)研究者的學(xué)生和下級(jí)、申辦者的員工、軍人、犯人、無(wú)藥可救疾病的患者、處于危急狀況的患者,
入住福利院的人、流浪者、未成年人和無(wú)能力知情同意的人等弱勢(shì)受試者,應(yīng)予以特別保護(hù)。
6招募組織/機(jī)構(gòu)
6.1符合GCP要求的參與受試者招募的組織機(jī)構(gòu)及個(gè)人,應(yīng)是專業(yè)的藥物臨床試驗(yàn)機(jī)構(gòu)研究者團(tuán)隊(duì)或
第三方招募組織。
6.2招募組織/機(jī)構(gòu)的職責(zé):
——征得本人同意,負(fù)責(zé)項(xiàng)目受試者招募,并保障招募過(guò)程的合法性和合規(guī)性;
——根據(jù)受試者個(gè)人意愿,負(fù)責(zé)受試者相關(guān)資料及信息的收集、匯總和整理;
——恪守受試者隱私保護(hù),保障受試者合法權(quán)益不受損害;
——協(xié)助研究者對(duì)受試者相關(guān)疑問(wèn)給予恰當(dāng)解答;
——協(xié)助受試者院內(nèi)外依從性管理、出組后跟蹤管理;
——人文關(guān)懷。
6.3招募組織/機(jī)構(gòu)的人員要求:
——對(duì)臨床試驗(yàn)充分了解,參與GCP培訓(xùn)并取得相關(guān)資格證書;
——具有醫(yī)學(xué)、護(hù)理學(xué)、藥學(xué)等相關(guān)專業(yè)大專及以上學(xué)歷;
——具有良好的信用記錄及從業(yè)記錄,良好的溝通能力等;
——對(duì)臨床試驗(yàn)項(xiàng)目有充分的了解。
6.4對(duì)于第三方招募組織或機(jī)構(gòu),還需具備:
3
DB43/T2135—2021
——合法營(yíng)業(yè)執(zhí)照,
——健全的組織架構(gòu),
——完善的招募體系。
7受試者招募
7.1招募方式
可采用張貼招募廣告/海報(bào)、發(fā)傳單、網(wǎng)絡(luò)新媒體等方式發(fā)布招募信息,公開招募符合條件的受試
者。
7.2招募流程
7.2.1信息發(fā)布
所有招募信息發(fā)布均應(yīng)在該項(xiàng)目審核批準(zhǔn)所在藥物臨床試驗(yàn)機(jī)構(gòu)的倫理委員會(huì)批準(zhǔn)后方可執(zhí)行。招
募信息內(nèi)容應(yīng)包括但不限于:
——試驗(yàn)名稱及藥物名稱,
——入選/排除標(biāo)準(zhǔn),
——體檢項(xiàng)目,
——項(xiàng)目時(shí)間安排,
——聯(lián)系人及聯(lián)系方式,
——試驗(yàn)機(jī)構(gòu)名稱及地址。
招募信息內(nèi)容不應(yīng)有以下內(nèi)容:
——任何聲稱或暗示試驗(yàn)藥物肯定安全或有效或可治愈疾病;
——使用強(qiáng)制、引誘或鼓勵(lì)性質(zhì)的圖片或符號(hào);
——使用名額有限、先到先得、優(yōu)先獲取等文字;
——強(qiáng)調(diào)該臨床試驗(yàn)經(jīng)衛(wèi)生主管部門或其他部門核準(zhǔn);
——其他經(jīng)衛(wèi)生主管部門公告不得刊登的內(nèi)容。
7.2.2篩查前審核
招募人員負(fù)責(zé)審核內(nèi)容包含但不限于:
——受試者個(gè)人信息真實(shí)性;
——是否自愿報(bào)名;
——是否了解項(xiàng)目的相關(guān)安排;
——其他需要收集的信息及資料。
篩查前審核過(guò)程中,招募人員應(yīng)口齒清晰,溝通順暢,保障受試者充分知情,實(shí)時(shí)記錄并耐心解答
受試者相關(guān)疑問(wèn)。當(dāng)受試者信息與資料信息不一致,經(jīng)確認(rèn)后可進(jìn)行修改,確保信息的完整性和真實(shí)性。
7.2.3知情同意/篩查體檢
招募人員應(yīng)在受試者知情同意當(dāng)天在藥物臨床試驗(yàn)機(jī)構(gòu)現(xiàn)場(chǎng)協(xié)調(diào)安排相關(guān)流程,告知受試者相關(guān)注
意事項(xiàng)。受試者的篩選體檢應(yīng)在根據(jù)研究機(jī)構(gòu)的要求簽署知情同意書后進(jìn)行,藥物臨床試驗(yàn)機(jī)構(gòu)的研究
者負(fù)責(zé)整個(gè)體檢過(guò)程,招募人員可協(xié)助完成以下工作:
——體檢前,應(yīng)充分告知受試者體檢時(shí)間、體檢內(nèi)容、體檢地點(diǎn)等相關(guān)注意事項(xiàng);
4
DB43/T2135—2021
——體檢時(shí),現(xiàn)場(chǎng)進(jìn)行相關(guān)指引工作。I期臨床試驗(yàn)應(yīng)使用臨床試驗(yàn)受試者數(shù)據(jù)庫(kù)對(duì)受試者既往試
驗(yàn)史進(jìn)行篩查,避免受試者短期內(nèi)重復(fù)多次參加,保障受試者權(quán)益;
——體檢完成后,在受試者離開中心前,應(yīng)及時(shí)告知項(xiàng)目安排等相關(guān)注意事項(xiàng)。
7.2.4結(jié)果通知
體檢結(jié)果出來(lái)后1個(gè)工作日內(nèi),第三方招募組織或機(jī)構(gòu)可協(xié)助研究者告知受試者項(xiàng)目入選情況,包
括進(jìn)一步試驗(yàn)安排及相關(guān)注意事項(xiàng)。對(duì)于I期臨床試驗(yàn),應(yīng)告知住院時(shí)間、入住前以及入住時(shí)注意事項(xiàng)。
當(dāng)受試者對(duì)體檢結(jié)果有疑問(wèn)時(shí),招募人員應(yīng)在3個(gè)工作日內(nèi)與研究者聯(lián)系,協(xié)助受試者了解完整體
檢信息,消除其疑慮。
8受試者管理
8.1依從性管理
8.1.1責(zé)任人
招募人員應(yīng)在整個(gè)試驗(yàn)期間協(xié)助研究者進(jìn)行受試者的依從性管理。
8.1.2院外管理
8.1.2.1與受試者保持通暢的溝通渠道和溝通方式。
8.1.2.2與受試者維系良好的信任關(guān)系。
8.1.2.3提醒院外期間的注意事項(xiàng),當(dāng)受試者有任何不良事件或?qū)τ谂R床試驗(yàn)的相關(guān)疑問(wèn)等,應(yīng)及時(shí)
記錄并及時(shí)反饋給研究者或研究者團(tuán)隊(duì)成員并積極安撫受試者情緒。
8.1.3院內(nèi)管理
維持現(xiàn)場(chǎng)篩選體檢秩序,協(xié)助研究者及期團(tuán)隊(duì)進(jìn)行受試者管理,I期臨床試驗(yàn)還需協(xié)助研究者進(jìn)
行受試者身份信息比對(duì)、臨床試驗(yàn)受試者數(shù)據(jù)庫(kù)篩查,協(xié)調(diào)飲食安排等。
8.2出組后跟蹤管理
8.2.1受試者出組后,定期進(jìn)行跟蹤管理,了解受試者身體情況,當(dāng)出現(xiàn)身體不適、疑問(wèn)及困惑等問(wèn)
題,應(yīng)充分理解并視情況協(xié)助解決,有效減輕受試者心理壓力。
8.2.2受試者出現(xiàn)身體不適或嚴(yán)重的不良反應(yīng),應(yīng)及時(shí)協(xié)助解決并及時(shí)反饋給研究者及其團(tuán)隊(duì)。
8.2.3不定期進(jìn)行受試者回訪,了解受試者近期身體情況,協(xié)助相關(guān)問(wèn)題的解決。
8.3人文關(guān)懷管理
8.3.1從受試者個(gè)人角度出發(fā),充分保障受試者身心健康與權(quán)益。
8.3.2與受試者保持良好通暢的溝通,充分減輕受試者心理壓力,定期了解近期身體情況。
8.3.3協(xié)助解決受試者其他方面的訴求,保障受試者不因參加臨床試驗(yàn)而受到任何人歧視或傷害。
9受試者權(quán)益和安全
9.1受試者權(quán)益
招募人員應(yīng)遵循自愿原則,允許受試者隨時(shí)拒絕而不必有任何理由,不應(yīng)遭到歧視或者報(bào)復(fù)受試者。
5
DB43/T2135—2021
發(fā)生不良事件后,應(yīng)及時(shí)治療和賠償,保護(hù)受試者的權(quán)益。
9.2受試者隱私保護(hù)
招募人員在項(xiàng)目執(zhí)行過(guò)程中產(chǎn)生受試者個(gè)人信息資料,均需專柜保存、專人管理。
與招募相關(guān)的文件以及受試者個(gè)人信息應(yīng)妥善保管至臨床試驗(yàn)結(jié)束后五年或試驗(yàn)產(chǎn)品上市后五年;
到期后需銷毀并記錄銷毀過(guò)程。
10質(zhì)量控制
10.1數(shù)據(jù)管理
為規(guī)范招募管理服務(wù),切實(shí)保障臨床試驗(yàn)數(shù)據(jù)真實(shí)、有效、完整及可溯源,實(shí)現(xiàn)受試者招募管理全
流程可控,宜采用信息化進(jìn)行招募數(shù)據(jù)管理,并確保數(shù)據(jù)的真實(shí)性、完整性和可溯源。
溯源包括但不限于以下層面:
——人員真實(shí)性:核實(shí)受試者是否真實(shí)存在,是否為本人參與試驗(yàn),受試者資料是否真實(shí);
——過(guò)程規(guī)范性:招募過(guò)程中所產(chǎn)生資料是否真實(shí)可靠,流程是否完整、規(guī)范;
——信息完整性:從招募廣告發(fā)起至最后一例受試者完成試驗(yàn),是否有信息中斷現(xiàn)象,相應(yīng)流程是
否規(guī)范。
10.2評(píng)價(jià)改進(jìn)
10.2.1評(píng)價(jià)機(jī)構(gòu)
可由行業(yè)主管部門、行業(yè)主管部門委托的第三方機(jī)構(gòu)或藥物臨床試驗(yàn)機(jī)構(gòu)等開展招募評(píng)價(jià)工作。
招募組織/機(jī)構(gòu)應(yīng)定期開展自評(píng)價(jià)。
10.2.2評(píng)價(jià)內(nèi)容及方法
開展評(píng)價(jià)的內(nèi)容及方法有:
——招募組織/機(jī)構(gòu)的資質(zhì):查驗(yàn)是否具備組織/機(jī)構(gòu)相關(guān)證書、質(zhì)量管理體系、人員任職資質(zhì);
——招募開展的合法合規(guī)性:查驗(yàn)服務(wù)過(guò)程及相關(guān)資料是否違反GCP以及相關(guān)倫理指導(dǎo)原則;
——招募能力/滿意度:開展服務(wù)單位以及受試者的問(wèn)卷調(diào)查。
10.2.3持續(xù)改進(jìn)
招募組織/機(jī)構(gòu)建立有效的評(píng)價(jià)處理和反饋改進(jìn)機(jī)制,針對(duì)相關(guān)方問(wèn)題和意見,進(jìn)行相應(yīng)的處理、
整改和反饋并及時(shí)記錄存檔。
6
DB43/T2135—2021
參考文獻(xiàn)
[1]涉及人的生物醫(yī)學(xué)研究倫理審查辦法(中華人民共和國(guó)國(guó)家衛(wèi)生和計(jì)劃生物委員會(huì)令第11
號(hào))
[2]藥物臨床試驗(yàn)倫理審查工作指導(dǎo)原則(國(guó)家食品藥品監(jiān)督管理局2010年)
[3]藥物臨床試驗(yàn)質(zhì)量管理規(guī)范(國(guó)家食品藥品監(jiān)督管理局2020年7月)
[4]朱偉,等.涉及人的健康相關(guān)研究國(guó)際倫理準(zhǔn)則[M].上海:上海交通大學(xué)出版社,2019.
[5]李豐杉,馮仕銀,陳卓,王晶,鄒琴,郭偉一,蔡林芮,蘇旭,胡鳳,杜丹,杜春鳳,鄭瑩,余勤.生物
等效性試驗(yàn)受試者招募困境與解決方法探討[J].中國(guó)醫(yī)學(xué)倫理學(xué),2020,33(05):575-578+582.
[6]李婷,劉淑芹,柳艷平,高曉萌,馬雅萍,時(shí)萍,曹玉.規(guī)范生物等效性試驗(yàn)中受試者管理提高臨
床試驗(yàn)質(zhì)量的措施[J].中國(guó)醫(yī)院藥學(xué)雜志,2019,39(15):1582-1585.
[7]程毅,布格拉·米吉提,張翌韋,袁明奎,楊建華,魯瑞萍.醫(yī)院藥物臨床試驗(yàn)受試者權(quán)益保護(hù)及
對(duì)策[J].中國(guó)醫(yī)學(xué)倫理學(xué),2019,32(01):55-58.
[8]韓帥瑋琦,解染,陳筱,趙俠,崔一民.探討合理應(yīng)用受試者數(shù)據(jù)庫(kù)管理我國(guó)Ⅰ期臨床試驗(yàn)篩選
過(guò)程[J].中國(guó)臨床藥理學(xué)雜志,2016,32(08):749-752.
7
DB43/T2135—2021
目次
前言························································································································Ⅲ
1范圍·····················································································································1
2規(guī)范性引用文件······································································································1
3術(shù)語(yǔ)和定義············································································································1
4縮略語(yǔ)··················································································································2
5基本原則···············································································································2
5.1知情同意原則···································································································2
5.2控制風(fēng)險(xiǎn)原則···································································································3
5.3免費(fèi)和補(bǔ)償原則································································································3
5.4保護(hù)隱私原則···································································································3
5.5依法賠償原則···································································································3
5.6特殊保護(hù)原則···································································································3
6招募組織/機(jī)構(gòu)········································································································3
7受試者招募············································································································4
7.1招募方式·········································································································4
7.2招募流程·········································································································4
8受試者管理············································································································5
8.1依從性管理······································································································5
8.2出組后跟蹤管理································································································5
8.3人文關(guān)懷管理···································································································5
9受試者權(quán)益和安全···································································································5
9.1受試者權(quán)益······································································································5
9.2受試者隱私保護(hù)································································································6
10質(zhì)量控制··············································································································6
10.1數(shù)據(jù)管理·······································································································6
10.2評(píng)價(jià)改進(jìn)·······································································································6
參考文獻(xiàn)····················································································································7
I
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2024年度f(wàn)armhouse木門安裝服務(wù)合同
- 深圳購(gòu)房合同樣本
- 住宅房屋購(gòu)買合同簡(jiǎn)單版
- 2024年《軟件許可合同中不可抗力事件的處理》
- 廣告公司授權(quán)合同模板
- 2024年范文承包土地協(xié)議書
- 2024年發(fā)光字合同
- 跨境客運(yùn)線路租賃合同
- 共建文明施工項(xiàng)目協(xié)議書
- 親子園與醫(yī)療機(jī)構(gòu)合作協(xié)議書
- 國(guó)開2024年《中國(guó)法律史》平時(shí)作業(yè)1-3答案
- 完整版維修電工高級(jí)三級(jí)培訓(xùn)計(jì)劃
- 第八講 地形圖應(yīng)用(二)
- 普鐵避雷器檢修作業(yè)指導(dǎo)書
- 下水管道施工合同通用版
- 工資流水證明2頁(yè)
- 鐵合金生產(chǎn)工藝
- 鋼結(jié)構(gòu)策劃書(范本)
- 急性腎衰竭與crrt治
- 焦化廠生產(chǎn)工序及工藝流程圖
- 嘔吐(急性胃腸炎)診療指南(制訂)編制說(shuō)明排版
評(píng)論
0/150
提交評(píng)論